New Zealand markets closed
  • NZX 50

    11,967.72
    -66.45 (-0.55%)
     
  • NZD/USD

    0.6446
    -0.0023 (-0.35%)
     
  • NZD/EUR

    0.5941
    -0.0010 (-0.16%)
     
  • ALL ORDS

    7,680.00
    -20.40 (-0.26%)
     
  • ASX 200

    7,468.90
    -12.80 (-0.17%)
     
  • OIL

    77.55
    -0.35 (-0.45%)
     
  • GOLD

    1,934.30
    -4.90 (-0.25%)
     
  • NASDAQ

    11,912.39
    -254.21 (-2.09%)
     
  • FTSE

    7,784.87
    +19.72 (+0.25%)
     
  • Dow Jones

    33,717.09
    -260.99 (-0.77%)
     
  • DAX

    15,126.08
    -23.95 (-0.16%)
     
  • Hang Seng

    21,789.31
    -280.42 (-1.27%)
     
  • NIKKEI 225

    27,374.15
    -59.25 (-0.22%)
     
  • NZD/JPY

    83.9680
    -0.3100 (-0.37%)
     

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

Nkarta, Inc.
Nkarta, Inc.

Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate.

Conference Call and Webcast
To access the conference call, please register through this link:
https://nkarta-nkx019-clinical-update-conference-call.open-exchange.net/registration

Accompanying slides will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.

About NKX019
NKX019, a wholly owned program of Nkarta, is an investigational healthy donor-derived CAR NK cell therapy targeting CD19. NKX019 is being investigated in an ongoing Phase 1 single-arm, open label, multi-center, international clinical trial that is designed to assess the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle monotherapy and combination therapy in patients with relapsed/refractory B cell malignancies.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com